Chinese Pulmonary Arterial Hypertension Patient Outcomes on Selexipag Triple Therapy

A retrospective cohort of 153 Chinese patients with pulmonary arterial hypertension (PAH) treated with selexipag-based triple therapy. The dataset includes safety and efficacy outcomes, echocardiogram parameters, and non-invasive risk assessments collected at Qilu Hospital of Shandong University from February 2022 to November 2023. The study was authored by Xiaopei Cui and shared under a CC-BY-4.0 license.

Use Cases

• Compare initial versus sequential triple therapy strategies based on the reported hazard ratio for disease progression.
• Analyze changes in risk stratification based on the reported counts of patients meeting low-risk criteria.
• Model improvements in exercise capacity based on the reported 6-minute walk distance (6MWD) and NT-proBNP levels.
• Study the safety profile of selexipag in a real-world Chinese patient cohort as described in the safety analysis.

Strengths

• Includes data for 153 patients in safety analysis and 146 in efficacy analysis, providing a defined cohort size.
• Reports specific clinical outcomes, including a median follow-up of 29 weeks for selexipag treatment and an average overall follow-up of 33 ± 10 months.
• Contains multiple clinical measures: WHO functional class, 6MWD, NT-proBNP levels, and echocardiogram parameters like right atrial area.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data tables is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may reflect geographic or institutional bias.

Provenance

Source

Qilu Hospital of Shandong University

Collection Method

Single-center, retrospective study.

Time Range

Patient data from February 2022 to November 2023, with follow-up.

Freshness

Last updated 2026-05-21 05:44:04; freshness should be verified.

Geography

China